RETROSPECTIVE CLAIMS ANALYSIS OF TREATMENT DURATION, HEALTH CARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH FIRST-LINE TREATMENT OF NSCLC WITH AFATINIB VS. ERLOTINIB IN THE UNITED STATES
Samuelsen C, Lim J, Golembesky AK, Shrestha S, Wang L, Griebsch I
Learn more about the science behind this poster in the videos, papers and other materials below.
Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA
Jonathan Lim, Carl Samuelsen, Amanda Golembesky, Sulena Shrestha, Li Wang & Ingolf Griebsch
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
